

PREPARED BY: Suzanne Houlden
 DATE PREPARED: February 10, 2022
 PHONE: 402-471-0057

LB 766

Revision: 00

FISCAL NOTE
 LEGISLATIVE FISCAL ANALYST ESTIMATE

ESTIMATE OF FISCAL IMPACT – STATE AGENCIES (See narrative for political subdivision estimates)				
	FY 2022-23		FY 2023-24	
	EXPENDITURES	REVENUE	EXPENDITURES	REVENUE
GENERAL FUNDS				
CASH FUNDS				
FEDERAL FUNDS	\$15,000,000			
OTHER FUNDS				
TOTAL FUNDS	\$15,000,000			

Any Fiscal Notes received from state agencies and political subdivisions are attached following the Legislative Fiscal Analyst Estimate.

LB 766 appropriates \$15,000,000 in federal American Rescue Plan Act of 2021 (ARPA) funds to the University of Nebraska for pancreatic cancer research. This proposal requires \$15,000,000 in private or other matching funds.

ADMINISTRATIVE SERVICES STATE BUDGET DIVISION: REVIEW OF AGENCY & POLT. SUB. RESPONSE			
LB:	766 (Revised)	AM:	AGENCY/POLT. SUB: University of Nebraska
REVIEWED BY:	Gary Bush	DATE:	1/18/22 PHONE: (402) 471-4161
<p>COMMENTS: Agree with University that the bill provides ARPA federal funds and that these funds are to be matched by the University. The maximum funding available under the federal Coronavirus State Fiscal Recovery Fund is \$1.04 billion, of which only \$520 million is currently available. Appropriation of these funds must be balanced in aggregate in order to avoid over obligation. Technical Note: The language in the bill does not provide the level of detail necessary to enact the appropriation intended.</p>			

LB ⁽¹⁾ 0766 Appropriate federal funds to the University of Nebraska for pancreatic cancer research

FISCAL NOTE

State Agency OR Political Subdivision Name:⁽²⁾ University of Nebraska System

Prepared by:⁽³⁾ Chris Kabourek Date Prepared:⁽⁴⁾ 01/13/2022 Phone:⁽⁵⁾ (402) 472-7156

ESTIMATE PROVIDED BY STATE AGENCY OR POLITICAL SUBDIVISION

	FY 2022-23		FY 2023-24	
	<u>EXPENDITURES</u>	<u>REVENUE</u>	<u>EXPENDITURES</u>	<u>REVENUE</u>
GENERAL FUNDS	0.00	0.00	0.00	0.00
CASH FUNDS	0.00	0.00	0.00	0.00
FEDERAL FUNDS	15,000,000.00	0.00	0.00	0.00
OTHER FUNDS	15,000,000.00	0.00	0.00	0.00
TOTAL FUNDS	30,000,000.00	0.00	0.00	0.00

Explanation of Estimate:

LB 766 would appropriate \$15 million from the State of Nebraska's ARPA State and Local Fiscal Recovery Fund allocation upon certification of a match of \$15 million in private or other funds. LB 766 would build and expand capacity in UNMC's research enterprise that was affected by the COVID-19 public health pandemic and would allow UNMC to:

- 1) recruit eight new pancreatic cancer researchers with expertise in various areas including, but not limited to, immunotherapy, drug discovery and delivery, and early detection research, 2) create an innovative Pancreas Cancer Cellular Immunotherapy Resource with the aim of developing new treatments and therapies for pancreatic cancer patients, 3) expand its novel Pancreas Cancer Early Detection Clinic with the objective of diagnosing pancreatic cancer at an earlier stage, and 4) purchase critical lab equipment and supplies to fight pancreatic cancer in Nebraska.

UNMC anticipates this \$30M investment in the pancreas cancer research infrastructure at the Fred & Pamela Buffett Cancer Center (BCC) will enable new and current pancreas cancer researchers to double their total annual extramural pancreatic cancer research funding to over \$16 million. Furthermore, BCC physician scientists will have the resources needed to develop, open and offer novel and innovative treatments for pancreatic cancer through clinical trials that are open only at the Buffett Cancer Center. As a result, patients from across the U.S. will travel to Omaha, NE to seek treatment for pancreatic cancer.

Unfortunately, the COVID-19 pandemic has had a drastic effect on the entire cancer continuum through interruption, delays, and altered modes of screening, diagnosis, and treatment of patients with cancer including pancreatic cancer. This funding for pancreas cancer research will help expand the BCC pancreatic cancer screening clinic and will ensure that Nebraskans with any symptoms or concerns about pancreatic cancer are able to seek pancreatic cancer screening in a timely manner leading to earlier diagnosis, more effective treatments, and better outcomes for patients with pancreatic cancer.

BREAKDOWN BY MAJOR OBJECTS OF EXPENDITURE

Personal Services:

POSITION TITLE	NUMBER OF POSITIONS		2022-23	2023-24
	<u>22-23</u>	<u>23-24</u>	<u>EXPENDITURES</u>	<u>EXPENDITURES</u>
	0	0		
	0	0		
Benefits.....				
Operating.....				
Travel.....				
Capital outlay.....			30,000,000.00	
Aid.....				
Capital improvements.....				
TOTAL.....			30,000,000.00	